1) Studies on the chemosensitizing effects of PARP inhibitors in combination with methylating agents, topoisomerase I poisons or platinum compounds using in vitro and in vivo preclinical models of melanoma, glioblastoma, lymphoma, colon cancer.

2) Characterization of the anti-angiogenic activity of PARP inhibitors.

3) Studies on synthetic lethality and chemosensitizing effects of PARP inhibitors in primary cultures of human glioblastoma stem cells and acute myeloid leukemias.